Fiche publication
Date publication
février 2018
Journal
Journal of atherosclerosis and thrombosis
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MEYER Nicolas
Tous les auteurs :
Ristorto J, Messas N, Marchandot B, Kibler M, Hess S, Meyer N, Schaeffer M, Tuzin N, Ohlmann P, Jesel L, Morel O
Lien Pubmed
Résumé
In percutaneous coronary intervention (PCI)-treated acute coronary syndrome (ACS) patients on clopidogrel therapy, high on-treatment platelet adenosine diphosphate (ADP) reactivity was observed in numerous studies, with significant increases in non-fatal myocardial infarction, definite/probable stent thrombosis, or cardiovascular mortality. Compared to clopidogrel, prasugrel and ticagrelor provide more potent platelet inhibition. Whether new P2Y12 inhibitors reduce thrombotic events in a similar manner compared to the rate observed with appropriate P2Y12 inhibition by clopidogrel must still be determined. This study sought to compare long-term outcomes between clopidogrel responders (platelet reactivity index [PRI] vasodilator-stimulated phosphoprotein [VASP] ＜61%) and patients under prasugrel or ticagrelor therapy following PCI-treated ACS.
Mots clés
Bleeding, Myocardial infarction, Stent, Thrombosis
Référence
J. Atheroscler. Thromb.. 2018 Feb 8;:
